Cobas and Therascreen May Be Preferable Tests for EGFR Mutation

Testing for EGFR gene mutations in non-small cell lung cancer (NSCLC) helps identify patients who could benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs) like erlotinib (Tarceva), gefitinib (Iressa), or afatinib. However, there are no official recommendations for specific EGFR mutation tests. A study comparing three tests—cobas EGFR Mutation Test, Therascreen EGFR29 Mutation Kit, and 2× bidirectional Sanger sequencing—found that the cobas and Therascreen tests were more accurate and sensitive than Sanger sequencing. The cobas test required the smallest amount of tumor tissue, while the Sanger test can theoretically detect more types of mutations than the other tests.